|
Mechanismγ-secretase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss
A phase 2 trial with LY3056480 in patients with stable SNHL
A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss. - REGAIN
A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss. - REGAIN
100 Clinical Results associated with Audion Therapeutics BV
0 Patents (Medical) associated with Audion Therapeutics BV
100 Deals associated with Audion Therapeutics BV
100 Translational Medicine associated with Audion Therapeutics BV